A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
← catalyst calendarSponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60actual
Sites
15
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-09 | actual | When the study began enrolling |
| Primary completion | 2025-03-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-12 | actual | The whole study's end, after follow-up |
| First posted | 2022-12-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis
Intervention
- Drug: Dimethyl fumarate — also filed as Tecfidera, DMF, BG00012
Primary outcome
what the primary-completion date above is the date OFAnnualized Relapse Rate (ARR)
measured Week 48
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed